The ROE as of November 2024 (TTM) for Zentalis Pharmaceuticals, Inc. (ZNTL) is -43.92%

According to Zentalis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -43.92%. This represents a change of 280.69% compared to the average of -11.54% of the last 4 quarters.

Zentalis Pharmaceuticals, Inc. (ZNTL) Historical ROE (quarterly & annually)

How has ZNTL ROE performed in the past?

The mean historical ROE of Zentalis Pharmaceuticals, Inc. over the last ten years is -57.30%. The current -43.92% ROE has changed -23.35% with respect to the historical average. Over the past ten years (40 quarters), ZNTL's ROE was at its highest in in the March 2020 quarter at 16.81%. The ROE was at its lowest in in the March 2019 quarter at -25.82%.

Zentalis Pharmaceuticals, Inc. (ZNTL) ROE by Quarter and Year

Discovering the peaks and valleys of Zentalis Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Zentalis Pharmaceuticals, Inc. (ZNTL) Average ROE

How has ZNTL ROE performed in the past?

The current ROE of Zentalis Pharmaceuticals, Inc. (ZNTL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Zentalis Pharmaceuticals, Inc. (ZNTL) ROE vs. Peers

How is ZNTL’s ROE compared to its peers?

Zentalis Pharmaceuticals, Inc.’s ROE is greater than Sana Biotechnology, Inc. (-94.47%), greater than Olema Pharmaceuticals, Inc. (-53.55%), greater than Cullinan Oncology, Inc. (-26.54%), greater than aTyr Pharma, Inc. (-56.83%), greater than Gracell Biotechnologies Inc. (-15.56%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Erasca, Inc. (-42.26%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Syndax Pharmaceuticals, Inc. (-64.34%), less than Protagonist Therapeutics, Inc. (34.68%), greater than Revolution Medicines, Inc. (-33.67%), greater than Blueprint Medicines Corporation (-47.66%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than iTeos Therapeutics, Inc. (-20.11%), greater than Icosavax, Inc. (-20.22%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than VectivBio Holding AG (-56.92%), greater than Annexon, Inc. (-38.99%),

Build a custom stock screener for Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zentalis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Zentalis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.